Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLP2117 in advanced solid tumors
NCT05830045Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of PSB114 in solid tumor (advanced stage) (2 arms), sponsored by Qilu Pharmaceutical. Primary endpoints: Dose-limiting toxicity at 21 days, Adverse Events at 96 weeks and 1 more. Started May 2023; status: recruiting.
02
Drugs
PSB114
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05830045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830045.